Targeting HNSCC-specific molecules further developed a number of targeted therapy agents including epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab, zalutumumab and nimotuzumab), EGFR tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib, lapatinib, afatinib and dacomitinib) as well as vascular endothelial growth factor (VEGF) inhibitors (bevacizumab) or vascular endothelial growth factor receptor (VEGFR) inhibitors (sorafenib, sunitinib and vandetanib) [92]. Here, VEGFA is linked to head and neck squamous cell carcinoma.